- Home
- REPX vs CTKB Comparison
REPX vs CTKB Comparison
Compare REPX & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPX | CTKB |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.9M | 652.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | REPX | CTKB |
|---|---|---|
| Price | $27.50 | $5.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $36.00 | $5.70 |
| AVG Volume (30 Days) | 180.8K | ★ 785.4K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $397,398,000.00 | $196,828,000.00 |
| Revenue This Year | $0.59 | $0.08 |
| Revenue Next Year | $14.96 | $5.45 |
| P/E Ratio | $6.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.98 | $2.37 |
| 52 Week High | $37.02 | $6.18 |
Technical Indicators
Market Signals| Indicator | REPX | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 52.58 |
| Support Level | $26.95 | $5.21 |
| Resistance Level | $28.38 | $5.70 |
| Average True Range (ATR) | 1.12 | 0.26 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 66.67 | 41.82 |
Price Performance
Historical ComparisonAbout REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.